Sarfaraz K Niazi (Sarfaraz Niazi)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 34

Top Topics

Plasmodium Falciparum

Transcription Factor

Top Venues

Pharmaceuticals (Basel, Switzerland)

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Sarfaraz K Niazi
The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs. Pharmaceutics 16 (7) (2024)
Sarfaraz K Niazi
Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products. Pharmaceutics 16 (8) (2024)
Sarfaraz K Niazi
The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs. Pharmaceutics 16 (7) (2024)
Sarfaraz K Niazi, Zamara Mariam, Matthias Magoola
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders. International journal of molecular sciences 25 (12) (2024)
Sarfaraz K Niazi, Matthias Magoola
Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody-Transferrin Conjugates. Biomedicines 12 (4) (2024)
Sarfaraz K Niazi, Sesselja Omarsdottir
Lectin-Based Fluorescent Comparison of Glycan Profile-FDA Validation to Expedite Approval of Biosimilars. International journal of molecular sciences 25 (17) (2024)
Sarfaraz K Niazi
Advice to the US FDA to Allow US Pharmacopeia to Create Biological Product Specifications (BPS) to Remove Side-by-Side Analytical Comparisons of Biosimilars with Reference Products. Pharmaceutics 16 (8) (2024)
Sarfaraz K Niazi, Matthias Magoola
Transcytosis-Driven Treatment of Neurodegenerative Disorders by mRNA-Expressed Antibody-Transferrin Conjugates. Biomedicines 12 (4) (2024)
Sarfaraz K Niazi, Zamara Mariam, Matthias Magoola
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders. International journal of molecular sciences 25 (12) (2024)
Sarfaraz K Niazi, Matthias Magoola, Zamara Mariam
Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Sarfaraz K Niazi, Matthias Magoola, Zamara Mariam
Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders. Pharmaceuticals (Basel, Switzerland) 17 (6) (2024)
Sarfaraz K Niazi
The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs. Pharmaceutics 16 (7) (2024)
Sarfaraz K Niazi, Zamara Mariam
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Sarfaraz K Niazi
The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug design, development and therapy 17 (2023)
Sarfaraz K Niazi
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Zamara Mariam, Sarfaraz K Niazi
Glucagon-like peptide agonists: A prospective review. Endocrinology, diabetes & metabolism (2023)
Sarfaraz K Niazi
A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States. Healthcare (Basel, Switzerland) 11 (14) (2023)
Sarfaraz K Niazi
Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis. Pharmaceutics 15 (11) (2023)
Sarfaraz K Niazi
Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders. Vaccines 12 (1) (2023)
Sarfaraz K Niazi, Zamara Mariam
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Sarfaraz K Niazi, Zamara Mariam
Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review. International journal of molecular sciences 24 (14) (2023)
Sarfaraz K Niazi
RNA Therapeutics: A Healthcare Paradigm Shift. Biomedicines 11 (5) (2023)
Sarfaraz K Niazi
Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders. Vaccines 12 (1) (2023)
Sarfaraz K Niazi
Biosimilars Adoption: Recognizing and Removing the RoadBlocks. ClinicoEconomics and outcomes research : CEOR 15 (2023)
Sarfaraz K Niazi
A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Sarfaraz K Niazi
Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders. Vaccines 12 (1) (2023)
Sarfaraz K Niazi, Zamara Mariam
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Sarfaraz K Niazi
The Inflation Reduction Act: A boon for the generic and biosimilar industry. Journal of clinical pharmacy and therapeutics 47 (11) (2022)
Sarfaraz K Niazi
Molecular Biosimilarity-An AI-Driven Paradigm Shift. International journal of molecular sciences 23 (18) (2022)
Sarfaraz K Niazi
No two classes of biosimilars: Urgent advice to the US Congress and the FDA. Journal of clinical pharmacy and therapeutics 47 (9) (2022)
Sarfaraz K Niazi
Making COVID-19 mRNA vaccines accessible: challenges resolved. Expert review of vaccines 21 (9) (2022)
Sarfaraz K Niazi
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars. Drug design, development and therapy 16 (2022)
Sarfaraz K Niazi, Waleed Mohammed Al-Shaqha, Zafar Mirza
Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars. Journal of market access & health policy 11 (1) (2022)
Sarfaraz K Niazi
Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?" BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (1) (2019)